BR112022012499A2 - Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo - Google Patents

Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo

Info

Publication number
BR112022012499A2
BR112022012499A2 BR112022012499A BR112022012499A BR112022012499A2 BR 112022012499 A2 BR112022012499 A2 BR 112022012499A2 BR 112022012499 A BR112022012499 A BR 112022012499A BR 112022012499 A BR112022012499 A BR 112022012499A BR 112022012499 A2 BR112022012499 A2 BR 112022012499A2
Authority
BR
Brazil
Prior art keywords
peptide
treat
patient
composition
methods
Prior art date
Application number
BR112022012499A
Other languages
English (en)
Inventor
Bianchi Elisabetta
Deng Qiaolin
Lin Songnian
Orvieto Federica
Palani Anandan
Pessi Antonello
K Sawyer Tomi
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BR112022012499A2 publication Critical patent/BR112022012499A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PEPTÍDEO, COMPOSIÇÃO, MÉTODOS PARA TRATAR UM PACIENTE E PARA TRATAR UMA DOENÇA, E, USO DE UM PEPTÍDEO. Os peptídeos grampeados da presente invenção, e sais farmaceuticamente aceitáveis dos mesmos, são coagonistas dos receptores de glucagon e GLP-1 e podem ser úteis no tratamento, prevenção e supressão de doenças mediadas pelo receptor de glucagon e pelo receptor de GLP-1, incluindo, mas não limitadas a, distúrbios metabólicos, como diabetes, doença hepática gordurosa não alcoólica (DHGNA), esteato-hepatite não alcoólica (NASH) e obesidade.
BR112022012499A 2019-12-23 2020-12-18 Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo BR112022012499A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19425098.1A EP3842061A1 (en) 2019-12-23 2019-12-23 Stapled triazole co-agonists of the glucagon and glp-1 receptors
PCT/US2020/065796 WO2021133644A1 (en) 2019-12-23 2020-12-18 Stapled triazole co-agonists of the glucagon and glp-1 receptors

Publications (1)

Publication Number Publication Date
BR112022012499A2 true BR112022012499A2 (pt) 2022-09-06

Family

ID=69326342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012499A BR112022012499A2 (pt) 2019-12-23 2020-12-18 Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo

Country Status (10)

Country Link
US (1) US20230063794A1 (pt)
EP (2) EP3842061A1 (pt)
JP (1) JP2023508349A (pt)
KR (1) KR20220119475A (pt)
CN (1) CN115226391A (pt)
AU (1) AU2020412677A1 (pt)
BR (1) BR112022012499A2 (pt)
CA (1) CA3162800A1 (pt)
MX (1) MX2022007929A (pt)
WO (1) WO2021133644A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3229925A1 (en) * 2021-08-27 2023-03-02 David CAIANIELLO Molecular degraders of extracellular proteins

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
PT970095E (pt) 1997-03-07 2004-03-31 Metabasis Therapeutics Inc Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2002524463A (ja) 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
ES2250128T3 (es) 1999-05-17 2006-04-16 Novo Nordisk A/S Antagonistas/agonistas inversos de glucagon.
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
EP1357908A4 (en) 2001-01-30 2009-07-15 Merck & Co Inc ACYL-SULFAMIDES FOR THE TREATMENT OF OBESITY, DIABETES AND LIPID DISORDERS
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
WO2004019869A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2004066963A2 (en) 2003-01-17 2004-08-12 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
JP5198261B2 (ja) * 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
WO2008010017A1 (en) 2006-07-19 2008-01-24 Freescale Semiconductor, Inc. Method and apparatus for designing an integrated circuit
EP2170883A1 (en) 2007-06-28 2010-04-07 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
KR101404781B1 (ko) 2007-06-28 2014-06-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치의 제조 방법
WO2009011836A1 (en) 2007-07-19 2009-01-22 Merck & Co., Inc. Beta carboline derivatives as antidiabetic compounds
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
WO2015107428A2 (en) * 2014-01-15 2015-07-23 Fyziologicky Ustav Akademie Ved Cr, V.V.I. Lipidated peptides for lowering blood glucose
CA3093383A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
EP3377521A4 (en) * 2015-10-27 2019-05-01 Merck Sharp & Dohme Corp. LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
US11058775B2 (en) * 2016-04-26 2021-07-13 Merck Sharp & Dohme Corp. Insulin dimer-incretin conjugates
WO2019060660A1 (en) 2017-09-25 2019-03-28 Merck Sharp & Dohme Corp. CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS
CN115304666A (zh) * 2017-11-24 2022-11-08 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物

Also Published As

Publication number Publication date
JP2023508349A (ja) 2023-03-02
EP4081243A4 (en) 2024-01-10
KR20220119475A (ko) 2022-08-29
CA3162800A1 (en) 2021-07-01
EP4081243A1 (en) 2022-11-02
EP3842061A1 (en) 2021-06-30
CN115226391A (zh) 2022-10-21
AU2020412677A1 (en) 2022-07-14
MX2022007929A (es) 2022-09-29
US20230063794A1 (en) 2023-03-02
WO2021133644A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
MX2020007410A (es) Formulaciones, composiciones y métodos farmacéuticos de péptido yy.
EA202091290A1 (ru) Аналоги инкретина и их применение
CY1119498T1 (el) Συντηγμενα πολυπεπτιδια λεπτινης-abd με ενισχυμενη διαρκεια δρασης
EA202091284A1 (ru) Аналоги инкретина и их применение
EA201792203A1 (ru) Фармацевтические композиции для комбинированной терапии
MX2019012884A (es) Terapia de combinacion.
EA201291234A1 (ru) Аналоги глюкагона
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
MX2018005194A (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
TW200630327A (en) Substituted phenylalkanoic acids
BR112016021985A8 (pt) formulação farmacêutica e composto
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
BR112023000270A2 (pt) Composto, composição farmacêutica, e, peptídeo
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
BR112022012499A2 (pt) Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
MX2021002655A (es) Terapia de combinacion para el tratamiento de enfermedad hepatica.
JP2019529569A5 (pt)
BR112022012307A2 (pt) Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo
BR112022012335A2 (pt) Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo
RU2017126212A (ru) Композиция